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Abstract
Background: Although the incidence of melanoma in the U.S. is rising faster than any other cancer, the FDA-approved 
chemotherapies lack efficacy for advanced disease, which results in poor overall survival. Lysophosphatidic acid (LPA), 
autotaxin (ATX), the enzyme that produces LPA, and the LPA receptors represent an emerging group of therapeutic 
targets in cancer, although it is not known which of these is most effective.
Results: Herein we demonstrate that thio-ccPA 18:1, a stabilized phosphonothionate analogue of carba cyclic 
phosphatidic acid, ATX inhibitor and LPA1/3 receptor antagonist, induced a marked reduction in the viability of B16F10 
metastatic melanoma cells compared with PBS-treated control by 80-100%. Exogenous LPA 18:1 or D-sn-1-O-oleoyl-2-
O-methylglyceryl-3-phosphothioate did not reverse the effect of thio-ccPA 18:1. The reduction in viability mediated by 
thio-ccPA 18:1 was also observed in A375 and MeWo melanoma cell lines, suggesting that the effects are generalizable. 
Interestingly, siRNA to LPA3 (siLPA3) but not other LPA receptors recapitulated the effects of thio-ccPA 18:1 on viability, 
suggesting that inhibition of the LPA3 receptor is an important dualistic function of the compound. In addition, siLPA3 
reduced proliferation, plasma membrane integrity and altered morphology of A375 cells. Another experimental 
compound designed to antagonize the LPA1/3 receptors significantly reduced viability in MeWo cells, which 
predominantly express the LPA3 receptor.
Conclusions: Thus the ability of thio-ccPA 18:1 to inhibit the LPA3 receptor and ATX are key to its molecular 
mechanism, particularly in melanoma cells that predominantly express the LPA3 receptor. These observations 
necessitate further exploration and exploitation of these targets in melanoma.
Introduction
The incidence of melanoma, the most aggressive form of
skin cancer, is rising faster than any other cancer in the
U.S. with a 619% increase from 1950 to 2000 [1]. While
mortality from many cancers is in decline, melanoma of
the skin is among only three types, including liver and
esophageal, with increasing mortality among males in the
U.S. [2]. Although remarkable strides in research, preven-
tion and treatment continue to reduce cancer-related
mortality overall, the mortality from melanoma is
expected to rise due to the combination of increasing
incidence and lack of effective therapies. Factors that
increase melanoma susceptibility include accumulating
genomic mutations from environmental sun exposure, a
decrease in keratinocyte stem cell proliferation capacity, a
decline in the regeneration ability of the skin and evolving
changes in cellular signaling [3].
Advanced metastatic melanoma has an alarming aver-
age survival of only 6 to 10 months with less than 5% of
patients living 5 years after diagnosis [4]. Unfortunately
FDA-approved chemotherapy and immunotherapy used
against advanced metastatic melanoma such as dacarba-
zine (DTIC), interferon (IFN) and interleukin-2 (IL-2) do
not significantly improve patient outcomes in the major-
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ity (>80%) of patients [5]. Thus, more basic research is
desperately needed to develop new, more effective thera-
peutic strategies for this disease.
The potential involvement of the lysophosphatidic acid
(LPA) signaling pathway in melanoma was hypothesized
when autotaxin (ATX, ENPP2) was demonstrated to be
identical to a motility-stimulating factor secreted by mel-
anoma cells [6]. ATX is the enzyme that generates the
main extracellular pool of LPA [7]. LPA is a normal lipid
constituent of biological fluids with a wide range of
molecular signaling and resultant cellular outcomes [8,9].
LPA has been proposed to activate at least eight known G
protein coupled receptors (LPA1 [10], LPA2 [11], LPA3
[12], LPA4/GPR23 [13], LPA5/GPR92/93 [14,15], GPR87
[16], P2Y5 [17], and P2Y10 (putative dual LPA and S1P
receptor) [18]. LPA has also been demonstrated to acti-
vate PPARγ [19] and participates in cross communication
with tyrosine kinase receptors through as yet unclear
mechanisms [20,21]. The role of LPA production, LPA
receptor activation and LPA receptor expression in mela-
noma progression, and as potential therapeutic targets,
remains poorly understood.
Cyclic phosphatidic acid (1-acyl-sn-glycerol-2,3-cyclic
phosphate; cPA) is a naturally-occurring compound that
was originally isolated from the lipid fraction of slime
mold. cPA was initially demonstrated to have strong
inhibitory activity on eukaryotic DNA polymerase α, but
not β or γ [22]. However, cPA exhibits multiple other
actions in mammalian cells. For example, cPA prevents
tumor cell migration through its ability to downregulate
active RhoA and thus the downstream autophosphoryla-
tion of focal adhesion kinase [23]. Previously we demon-
strated that carba analogues of cyclic phosphatidic acid
(ccPA) potently inhibit ATX activity, LPA synthesis and
metastatic melanoma progression in vivo [24]. Interest-
ingly, ccPA compounds demonstrate anti-metastatic
effects accompanied by inhibition of RhoA activation.
This effect is not due to inhibition of LPA receptor activa-
tion [25], suggesting that inhibition of ATX and subse-
quent LPA production represents a critical target.
We have developed the next generation of ccPA com-
pound, the stabilized analogue thio-ccPA 18:1, as a mech-
anistic probe and potential therapeutic modality. Thio-
ccPA 18:1 is a phosphonothioate analogue of ccPA with
an enhanced ability to inhibit ATX activity (89% at 10
μM) [26]. Thio-ccPA 18:1 is also unique due to its action
as a selective inhibitor of LPA receptors, blocking LPA1
and LPA3, with no effect on LPA2 [26,27]. Thio-ccPA
18:1 has not demonstrated any detectable agonist-related
activation of the LPA receptors examined, including
LPA1, LPA2 or LPA3 [26].
Herein we tested the potential of thio-ccPA 18:1 as a
melanoma therapeutic in vitro and as a probe of relative
efficacy of inhibition of ATX, LPA1 and LPA3. We
observed that thio-ccPA 18:1 reduces viability in the
highly aggressive B16F10 model for metastatic disease
progression. Our data demonstrates that thio-ccPA 18:1
directly inhibits the growth and viability of B16F10 mela-
noma cells, as well as two commonly used human mela-
noma cell lines, A375 and MeWo. Although ATX
inhibition contributes greatly to therapeutic efficacy
against melanoma [24], the effect of thio-ccPA 18:1 on
viability is not only related ATX inhibition since neither
LPA nor a stabilized LPA analog, R-OMPT [28] that
would bypass the inhibition of ATX, were able to override
the inhibitory effects of thio-ccPA 18:1. In addition, we
d e m o n s t r a t e d  t h a t  i n h i b i t i o n  o f  L P A 3  b y  s i R N A  a l s o
results in a decrease in cell viability in melanoma cells.
These studies are the first to implicate LPA3 as a critical
mediator of melanoma growth and survival, and provide
evidence that LPA3 mediated receptor signaling may rep-
resent an important therapeutic target in melanoma, pro-
viding an enhanced benefit of the phosphonothionate
analogue.
Methods
Reagents and Materials
LPA (18:1, 1-oleoyl-2-hydroxy-sn-glycero-3-phosphate
and 14:0, 1-myristoyl-2-Hydroxy-sn-Glycero-3-Phos-
phate) and (S)-phosphoric acid mono-{2-octadec-9-
enoylamino-3-[4-(pyridin-2-ylmethoxy)-phenyl]-propyl}
ester was purchased from Avanti Polar Lipids Inc (Ala-
baster, AL). D-sn-1-O-oleoyl-2-O-methylglyceryl-3-
phosphothionate (R-OMPT) was purchased from Eche-
lon Biosciences, Inc. (Salt Lake City, UT). A375 epithelial
malignant melanoma, MeWo fibroblast malignant mela-
noma cells and OVCAR-3, A549 and MDA-MB-231 cells
w e r e  a c q u i r e d  f r o m  A T C C  ( M a n a s s a s ,  V A )  a n d  m a i n -
tained in Cellgro RPMI (Mediatech, Inc., Manassas, VA)
supplemented with 5% (MeWo and A375) or 10%
(OVCAR-3, A549 and MDA-MB-231) FBS (Sigma, St
Louis, MO). B16-F10 murine melanoma were the kind
gift of Dr. Isaiah J. Fidler at The University of Texas MD
Anderson Cancer Center, Department of Cancer Biology
and maintained in DMEM (Mediatech, Inc.) supple-
mented with 10% FBS (Sigma). The phosphonothionate
ccPA 18:1 analogue (thio-ccPA 18:1) was synthesized as
previously described (24). The solid lyophilized sodium
salt of thio-ccPA 18:1 was reconstituted in PBS prior to
use.
Mouse xenograft model
All animal studies were conducted in compliance with the
policies and regulations of the University of Texas M.D.
Anderson Cancer Center Institutional Animal Care and
Use Committee (IACUC). To analyze the consequence of
treating metastatic melanoma tumors with thio-ccPA in
vivo, thirty C57/Bl6 mice (male, 4-6 weeks old) wereAltman et al. Molecular Cancer 2010, 9:140
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injected intravenously with 5 × 104 B16F10 cells into the
tail vein. Three days post injection, ten mice were ran-
domly selected for treatment with thio-ccPA 18:1. Of this
group, mice were given the indicated doses of thio-ccPA
by intraperitoneal injection. Thio-ccPA 18:1 injections
were repeated seven days post tumor cell injection. After
21 days all surviving mice were euthanized, gross
necropsy was performed and lungs were removed for fur-
ther examination for the presence of metastatic lesions.
Surviving mice were N = 17 for the control and N = 10 for
thio-ccPA 18:1. One murine lung was processed for path-
ological examination and immunohistochemistry. The
other lung was examined for lesions using a dissecting
microscope and imaged using a Nikon Coolpix camera
(Southern Microscope, Inc., Haw River, NC). Two inde-
pendent observers assessed the number of nodules pres-
ent on the lungs and results were averaged. Results are
means ± SE of experiments. **p < 0.01 treatment groups
vs. control by Tukey's test and analysis of variance.
Cell viability
B16F10, A375 or MeWo cells were examined for viability
by seeding the indicated number of cells (1 × 103 - 25 ×
103) in 96-well plates in quadruplicates. Cells were
allowed to attach to the plate for 4-8 h in 1% FCS contain-
ing medium (or 10% FCS containing medium where indi-
cated) prior to stimulation with PBS, 10-250 μM thio-
ccPA 18:1, FBS or 0.1-10 μM 18:1 LPA where indicated.
I n  s o m e  e x p e r i m e n t s ,  c e l l s  w e r e  t r a n s f e c t e d  w i t h  t h e
indicated ON-TARGETplus SMARTpool siRNA reagent
(Dharmacon, Lafayette, CO) and DharmaFECT (Dhar-
macon) for 48 h (see below for details). CellTiter™ Blue
reagent (Promega, Madison, WI) was added to plates and
cells were incubated at 37°C to assess viability as previ-
ously described [29]. Images of individual wells of 96-well
plates were acquired using a 12 megapixel Nikon Coolpix
camera (Southern Microscope, Inc., Haw River, NC). All
images show representative photos corresponding to
quadruplicate conditions.
Cell proliferation assay
A 3 7 5  c e l l s  w e r e  s e e d e d  i n  q u a d r u p l i c a t e s  i n  9 6 - w e l l
plates (2,000 cells/well) and allowed to attach for 8-16 h.
Cells were then placed in 1% serum-containing medium
and Transfected with the indicated indicated ON-TAR-
GETplus SMARTpool siRNA reagent (Dharmacon)for 48
h. Proliferation was assessed as previously described
using crystal violet [29]. Experimental groups were com-
pared with siRNA negative control (Applied Biosystems,
Foster City, CA) and Mock transfected controls. Results
are means ± SE of experiments. *p < 0.05 treatment
groups vs. control by Bonferroni's test and analysis of
variance.
Small interfering RNA (siRNA) transfection
We down regulated individual LPA receptor expression
by using sequence-specific siRNA purchased from ON-
TARGETplus SMARTpool siRNA reagents (Dharmacon).
The cells were transfected according to the manufac-
turer's protocol using either reagents DharmaFECT
(Dharmacon) or the X-tremeGENE siRNA transfection
reagent (Roche, Palo Alto, CA). Negative control siRNA
(control) was purchased from Applied Biosystems (Foster
C i t y ,  C A ) .  E x p r e s s i o n  l e v e l s  o f  g e n e  k n o c k d o w n  w e r e
optimized as previously described [29,30].
Assessment of siRNA transfection
Cells were transfected with SMARTpool siRNA reagents
(Dharmacon), which contain four different siRNA, each
consisting of 21 base pairs. The siRNA was extracted sep-
arately from the media and cells and analyzed by ion
chromatography using UV detection. Samples of the cell
medium and RNA isolated from transfected cells were
collected after 0, 6, 10 and 24 h. Along with ion chroma-
tography showing siRNA inside the cell, RNA and visual
observations of cells also corroborated successful trans-
fection targeting this receptor.
Trypan blue exclusion
The A375 and Mewo cells were seeded in 6-well dishes at
a density of 105 cells/well and allowed to attach overnight.
The cells were transfected with 20 nM of the indicated
siRNAs using the X-tremeGENE transfection reagent
(Roche, Palo Alto, CA). After 72 h of incubation, the cells
from separate wells were trypsinized, cell samples were
mixed with an equal volume of a solution of 0.4% Trypan
Blue dye (Sigma, St. Louis, MO) just before the counting
of cells. The cells from each replicate sample were imme-
diately transferred into both grids of a Neubauer hemocy-
tometer and the viable (dye excluding) fraction of cells in
all ten squares of both grids were counted under a micro-
scope. Cell numbers from all squares were averaged and
the total number of cells for each replicate sample was
determined.
Real-time PCR
mRNA of MeWo and A375 cells was extracted with Gen-
Elute Direct mRNA kit (Sigma Aldrich, St. Louis, MO)
and reverse transcribed into cDNA using Superscript III
kit (Invitrogen, Carlsbad, CA) following the manufac-
turer's protocol. Total human skin RNA was purchased
from Agilent Technologies (Palo Alto, CA). Real-time
PCR was performed using the primers for LPA1, LPA2,
LPA3, LPA4 and LPA5 as previously described [31] and
other primers for p2y5: forward 5'- TTGTATGGGTG-
CATGTTCAGC-3' and reverse 5'- GCCAATTCCGTGT-
TGTGAAGT -3'; p2y10: forward 5'- GTTTCCT
GACGTGCATCAGTC -3' and reverse 5' - AGTCCCCA-Altman et al. Molecular Cancer 2010, 9:140
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CAACGATCCAGAT -3' based on algorithm generated
sequences from Primer Bank http://pga.mgh.har-
vard.edu/primerbank/[32]. Other primers used included
GPR87: forward 5'- GAGCAAGTTGTTCCAGTAGTCG
-3' and reverse 5' - CTTTGAAACTAAGGTCGGCAGG
-3'; ATX: forward 5'- CTCGTTCCAGTCGTGTCAGA -
3' and reverse 5' - CAAGATCCGGAGATGTTGGT -3'.
PCR products were visualized by loading 1 μl of product
onto the Agilent DNA 1000 chip in gel-dye matrix and
running the chip for 35 min in the Bioanalyzer 2100 (Agi-
lent Technologies) following the manufacturer's protocol.
Cell morphology
B16F10 or A375 cells were seeded in quadruplicates in
96-well plates and treated with 50 μM thio-ccPA 18:1 or
transfected with the indicated siRNA for 48 h prior to the
examination of cell morphology. Cells were visualized
using an Axiovert 40 inverted microscope (Carl Zeiss
MicroImaging Inc., Thornwood, NY) and photomicro-
graphs were captured using a Nikon Coolpix camera
(Southern Microscope, Inc.).
Gene expression analysis
For examination of variations in biomarker expression
among patient datasets, a publicly-available melanoma
gene expression dataset (GSE7553, N = 87) [33] was
downloaded from the NCBI Entrez Gene Expression
Omnibus (GEO) DataSets website http://www.ncbi.nlm.
nih.gov/sites/entrez?db=gds and analyzed as previously
described [34]. Box plots using the normalized gene
expression were created with GraphPad Prism (GraphPad
Software, Inc., La Jolla, CA).
Evaluation of autotaxin inhibition
In order to assess the inhibition of autotaxin, an autotaxin
inhibitor screening kit (Echelon Biosciences, Inc, Salt
Lake City, UT) was employed as previously described
[35]. Briefly, 1 mM stock solutions were made in DMSO
and then diluted with water to the appropriate experi-
mental concentration. DMSO was spiked into each reac-
tion mixture to equalize vehicle concentrations. This
assay uses a fluorescence-quenched, lysophosphatidyl-
choline analogue FS-3 as the autotaxin substrate and
recombinant, human autotaxin purified from Sf9 insect
cells as the enzyme source. Thio-ccPA 18:1 was then pre-
incubated with the enzyme at 25°C for 10 min, then FS-3
was added. The rate of fluorescence increase was mea-
sured between 5- 25 min after substrate addition. In all
circumstances fluorescence increase was linear during
this time window. Rates were normalized to control reac-
tions that contained all reaction components except test
compound.
Statistical analysis
Statistical differences in experimental data was deter-
mined using analysis of variance (ANOVA) followed by
either Tukey's test or Bonferroni's multiple comparison
test between groups, where indicated. *p < 0.05 **p < 0.01
and ***p < 0.001 indicate the levels of significance.
Results
Previous observations that carba analogues of ccPA-
treated animals have reduced lesions in the lungs are
striking [24] and warrant further investigation. Thus, the
next generation compound was synthesized based on
enhanced metabolic stability of the carbacylic structure
(Fig. 1A) and improved receptor binding properties. We
thus hypothesized that the phosphonothionate analogue
of carba cyclic phosphatidic acid, thio-ccPA 18:1 (Fig.
1B), would have interesting biological properties related
to receptor binding and could be used to explore
approaches against melanoma progression.
In order to assess the most fundamental question,
whether thio-ccPA 18:1 had an effect on melanoma cell
viability, we examined the viability of metastatic mela-
noma B16F10 cells in vitro in the presence or absence of
thio-ccPA 18:1. No significant reduction in viability was
observed at 10 or 25 μM thio-ccPA 18:1 after 48 h; how-
ever, concentrations of 50 μM and above induced a dra-
matic reduction in viability, approximately 49% at 50 μM
and 85% at 100 μM (**P = 0.01 vs. PBS control Fig. 1C).
Thio-ccPA 18:1 (50 μM) treated B16F10 appeared small
and rounded compared with untreated controls that were
flattened and exhibited lamellipodia protrusions (Fig.
1D). Visual examination of individual wells treated with
100 μM detected few attached cells after 48 h (data not
shown).
Thio-ccPA 18:1 targets several components of the LPA
signaling pathway. It is an effective inhibitor of ATX, sim-
ilar to other cyclic phosphatidic acid analogues, but it
also is a direct antagonist of the LPA1 and LPA3 receptors
[27]. If ATX activity is the only important target of thio-
ccPA 18:1 [6], then exogenous LPA should override the
effects of thio-ccPA 18:1 [24]. In order to test this hypoth-
esis, we pre-treated the melanoma cells with LPA 18:1 (10
μM) or the metabolically stabilized LPA analogue D-sn-
1-O-oleoyl-2-O-methylglyceryl-3-phosphothionate (R-
OMPT) (1 μM) [28] prior to treatment with thio-ccPA
18:1 (50 μM). Pre-treatment of LPA or R-OMPT was
unable to bypass the reduction in cell viability induced by
thio-ccPA 18:1 (Fig. 1E). This suggests that additional tar-
gets, complementary to ATX inhibition, contribute to the
ability of thio-ccPA 18:1 to reduce melanoma cell viabil-
ity.
We next tested whether thio-ccPA 18:1 inhibits the via-
bility of human melanoma cells. This was done in order
to better represent translational applications of theAltman et al. Molecular Cancer 2010, 9:140
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phosphonothionate analogue to humans, to broadly
examine multiple melanoma cell lines and their responses
to thio-ccPA 18:1 and because B16F10 cells are hyper-
sensitive to fluctuations in the concentration of serum
contained in medium which could reflect an oncogenic
addiction to growth factors or bias in our in vitro data [3]
(Fig. S1A, Additional file 1). Neither the A375 or MeWo
cells are sensitive to serum starvation (Fig. S1B, Addi-
tional file 1), in contrast with B16F10 cells (Fig. S1B and
C, Additional file 1).
Although the three melanoma cell lines represent dis-
tinct and common genetic abnormalities observed in
melanoma, B16F10 (RAS), A375 (activating B-RAF, con-
stitutively active MAPK) and MeWo (no BRAF or NRAS),
they exhibited similar decreases in cell viability in the
presence of increasing concentrations of thio-ccPA 18:1
(Fig. 2A). This suggests the existence of a "common"
mechanism exploited by thio-ccPA 18:1 on the LPA sig-
naling pathway in these melanoma cells. Furthermore,
this mechanism is not shared by all tumor cell types since
Figure 1 Thio-ccPA 18:1 reduces the viability of B16F10 cells in vitro. (A) Chemical structure of ccPA 18:1 and (B) thio-ccPA 18:1. (C) B16F10 cells 
were treated with increasing concentrations (10-100 μM) of thio-ccPA 18:1 and analyzed for cell viability after 48 h. The graph presents the data as the 
percentage of reduction in cell viability (% of PBS control). **p < 0.01 vs. control by Bonferroni's t-test and analysis of variance. (D) B16F10 cells were 
either untreated (control) or treated with thio-ccPA 18:1 (50 μM). Images demonstrate the difference in B16F10 cell morphology after 48 h treatments 
with 50 μM thio-ccPA 18:1. (E) B16F10 cells were either untreated (control) or treated with LPA 18:1 (10 μM), LPA 14:0 (1 μM), R-OMPT (1 μM), thio-ccPA 
18:1 (50 μM) or a combination of these as shown. Cell viability was assessed after 48 h. ***p < 0.001 vs. control by Bonferroni's t-test and analysis of 
variance.Altman et al. Molecular Cancer 2010, 9:140
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A549, a lung cancer cell line, and MDA-MB-231, a breast
cancer cell line, are insensitive to the effects of thio-ccPA
18:1 (Fig. 2B). A549 cells express LPA1 > LPA4 > LPA2
receptors and the MDA-MB-231 cells express LPA1 >>
LPA2 receptors. Both cell lines express low levels of ATX
and no LPA3 receptors [36].
In addition to its inhibition of ATX (Fig. S2, Additional
file 2), thio-ccPA 18:1 is an LPA1/3 receptor antagonist
[27]. We wanted to determine the importance of the
receptor antagonism to the efficacy of the analogue, espe-
cially considering that the drug is insensitive in cells that
lack the LPA3 receptor. We therefore assessed whether
sequentially inhibition of individual LPA receptors
affected melanoma cell viability. Specific inhibitors tar-
geting all LPA receptors individually do not exist [37];
thus, we used siRNA to target individual LPA receptors.
With siRNA we can consistently reduce the amount of
LPA receptor expression approximately 60% or greater
[29] (Fig. S3A, Additional file 3) without activating com-
pensatory receptor expression mechanisms [30]. We have
previously established that LPA receptor knock-down
reduces LPA-mediated functions of LPA receptors in
vitro and in vivo [29,30]. Here we also assessed the ability
of siRNA to enter the cell from the transfected medium
using ion chromatography using UV detection. Strikingly,
we detected siRNA inside MeWo cells 6 h after transfec-
tion and this was detected in subsequent time points of
10 h and 24 h (Fig. S3B Additional file 3).
We next transfected A375 cells with siRNA for the LPA
receptors and detected a significant reduction in cell via-
bility when the LPA3 receptor expression was reduced
(Fig. 3A). The expression of verified LPA receptors in
A375 cells is LPA1, LPA2, LPA3, p2y5 >> LPA4, LPA5
(Fig. 3B), demonstrating that the LPA3 receptor is present
in A375 cells. Similar results were achieved using siRNA
in MeWo cells (Fig. 3C). The expression pattern of LPA
receptors was very different in MeWo cells, LPA3, LPA4
>> LPA2 (Fig. 3D) compared to A375 cells. The common-
alities between the two cell lines are expression of the
LPA2, LPA3 and LPA4 receptors. This pattern is not com-
monly observed among cancer cell lines [36]. This also
led us to examine LPA receptor expression in normal skin
where we detected expression of p2y5 and LPA1 recep-
tors and little (LPA2, LPA3) to no (LPA4, LPA5) expres-
sion of other receptors (Fig. 3E).
To further investigate the effects of thio-ccPA 18:1 on
melanoma cells and determine whether targeting the
LPA3 receptor has a complementary role to ATX inhibi-
tion, we examined LPA receptor-mediated cell viability
using A375 melanoma cells. Cells were treated for 48 h in
serum-free medium with LPA 18:1 (0.1 - 10 μM) and
assessed for cell viability. Indeed, the addition of LPA
alone enhanced the overall number of A375 cells (Fig.
4A). We next assessed cell death by measuring the integ-
rity of the cell membrane using trypan blue exclusion and
A375 cells transfected with increasing concentrations and
combinations of siRNA for the LPA1, LPA2 or LPA3
receptors. Only cells transfected with siLPA3 (20 nM, 60
nM or combination) produced conditions that signifi-
cantly affected the number of live cells (Fig. 4B). A375
cells transfected with 20 nM or 60 nM siLPA3 contained
45% and 30%, respectively, of live cells compared with
Mock control. Cell number was further assessed using
crystal violet (proliferation) staining and (20 nM) siLPA3.
We measured a decrease of 70% and 50% in the number
of cells transfected with siLPA3 compared with untreated
(Control) and Mock control, respectively (Fig. 4C). A375
cells transfected with siLPA3 have rounded cell morphol-
ogy that is distinct from normal control cells (Fig. 4D) but
reminiscent of thio-ccPA 18:1 treated cells shown in (Fig.
1E). To assess whether ATX was a major contributor to
viability in A375 cells, we measured the amount of
expression using RT-PCR. We were barely able to distin-
guish a marginal level of ATX in A375 cells, although fetal
Figure 2 Cell line comparison of viability reduction by thio-ccPA 
18:1. (A) B16F10, A375 and MeWo melanoma cells were treated with 
increasing concentrations (0-100 μM) of thio-ccPA 18:1 for 48 h and ex-
amined for viability. *p < 0.05 and ***p < 0.001 vs. control by Bonferro-
ni's t-test and analysis of variance. (B) A549, MDA-MB-231 and MeWo 
melanoma cells were treated with either 40 μM or 20 μM of thio-ccPA 
18:1 and examined for viability. Results show the percent of viability 
compared to vehicle (dH2O). **p < 0.01 vs. vehicle by Bonferroni's t-test 
and analysis of variance.Altman et al. Molecular Cancer 2010, 9:140
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skin and MeWo cells did express detectable levels of ATX
(Fig. 4E). Taken together, this suggests that inhibition of
the LPA3 receptor signaling reduces the viability of A375
melanoma cells and may be complimentary to ATX inhi-
bition as a dualistic mechanism of action of thio-ccPA
18:1.
The expression pattern observed in MeWo cells (ATX
and the LPA3 receptor) makes this the quintessential line
for confirming the efficacy of thio-ccPA 18:1. Inhibiting
the abundance of these two transcripts and then assessing
cell viability demonstrated that either siLPA3 or siATX
was capable of reducing viability (Fig. 5A). Combining
siLPA3 and siATX further reduced viability over each
individually and was comparable to siPLK1, a positive
control for siRNA transfection that results in termination
of cells.
Figure 3 The LPA3 receptor mediates viability in A375 and MeWo melanoma cells. Individual LPA receptors were targeted with siRNA to se-
quentially inhibit receptor expression. (A) A375 cells were transfected for 48 h with the indicated siRNA and examined for viability. *P < 0.05, vs. Mock 
in A375 by Bonferroni's t-test and analysis of variance. (B) RT-PCR showing LPA receptor expression in A375 cells visualized using the Bioanalyzer 2100. 
(C) MeWo cells were transfected for 48 h with the indicated siRNA and examined for viability. *P < 0.05, vs. Negative Control (RISC-free) in MeWo. (D) 
RT-PCR showing LPA receptor expression in MeWo cells visualized using the Bioanalyzer 2100. (E) RT-PCR showing LPA receptor expression in normal 
human skin visualized using the Bioanalyzer 2100.Altman et al. Molecular Cancer 2010, 9:140
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We next asked whether the LPA3 receptor plays a large
role in mediating LPA-induced cell viability in MeWo
cells. A selective LPA receptor agonist induced an
enhancement in viability by 21% under control conditions
in MeWo cells, 37% under control conditions in OVCAR-
3 cells but only 9% after MeWo cells were transiently
transfected with siRNA against the LPA3 receptor and
after overnight treatment with the agonist (Fig. 5B). We
further inhibited the LPA3 receptor using a selective
antagonist for LPA1/3, VPC32183, in MeWo cells (which
do not express the LPA1 receptor). We treated the MeWo
cells for 48 h and measured approximately 75% decrease
in cell viability (Fig. 5C). The marked reduction in viabil-
ity was blunted after transiently transfecting MeWo cells
with siRNA against the LPA3 receptor or by using the
OVCAR-3 cell line, which expresses multiple LPA recep-
tors. This suggests that LPA3 expression, but likely lack of
LPA2 expression, is required for response to the antago-
Figure 4 Knockdown of the LPA3 receptor induces cell death in A375 melanoma cells. (A) LPA 18:1 treatment (0.1-10 μM) of A375 cells in serum 
free medium for 48 h enhances viability. *p < 0.001 vs. untreated control. (B) A375 cells were transfected for 48 h with the indicated siRNAs and as-
sessed for membrane integrity and cell death using trypan blue exclusion assay. Cell numbers reflect the cells with intact membranes. *P < 0.001, com-
paring siRISC 60 nM vs. treatment conditions. (C) Transfection of siRNA targeting the LPA receptors in A375 cells for 48 h demonstrates that reducing 
the expression of the LPA3 receptor decreases the number of live cells assessed by crystal violet staining. *p < 0.05 vs. control. (D) Photomicrograph 
images demonstrating changes in cell morphology after 48 h of siLPA3 transfection. (E) RT-PCR demonstrating the level of expression of ATX and 
GPR87 in fetal skin, normal human skin, A375 and MeWo cells.Altman et al. Molecular Cancer 2010, 9:140
http://www.molecular-cancer.com/content/9/1/140
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nist VPC32183. The effect on blunting the cellular
response to the compound was not observed after tran-
siently transfecting MeWo cells with siRNA against the
LPA3 receptor and treating with thio-ccPA 18:1 (Fig. 5D).
In the presence of LPA3 receptor knock-down, thio-ccPA
18:1 further reduced cell viability, suggesting multiple tar-
gets induce the effects of thio-ccPA 18:1. We also noted
the response of VPC32183 was reduced by the presence
of serum (Fig. 5E). Our data suggests the unique pattern
of expression in MeWo cells (ATX and the LPA3 receptor,
without the LPA1 or LPA2 receptors) provides a quintes-
sential model for achieving a response to thio-ccPA 18:1
and represents a type of tumor that is susceptible to the
actions of thio-ccPA 18:1.
In order to determine whether thio-ccPA 18:1 would
influence metastatic melanoma tumors in vivo, we tested
its efficacy using the B16F10 metastatic melanoma mouse
model [38]. We injected B16F10 metastatic melanoma
cells into the tail vein of C57/Bl6 mice. Animals were
intraperitoneally injected on days 3 and 7 after intrave-
nous cell injection with 200 μg (10 mg/kg per dose) con-
centrations of thio-ccPA 18:1 or PBS (Control). Mice
were then sacrificed 21 days after the initial injection of
B16F10 cells, and tissues were fixed and analyzed for the
number of metastases. Treatment with thio-ccPA 18:1
significantly reduced the number of pulmonary metasta-
ses in mice as compared to the control treatment (p <
0.01, Fig. 6A, B and 6C). In addition to the effect on pul-
monary metastasis, all control animals (N = 17) had met-
astatic lesions to organs outside of the lungs, whereas
only twenty percent (N = 2/10) of thio-ccPA 18:1 treated
animals had detectable non-pulmonary metastases (Fig.
6D).
Figure 5 Inhibition of the LPA3 receptor using siRNA knockdown or LPA3 antagonists reduces viability of MeWo melanoma cells. (A) MeWo 
cells were plated in 96-wells and transfected with the indicated siRNAs for 24 h prior to the assessment of viability. The control, siNegative (non-tar-
geting siRNA), was normalized to 100%. *p < 0.05 and **p < 0.01 vs. siNegative control. (B) The agonist, VPC31144(S) 5 μM was added to either MeWo 
cells or OVCAR-3 cells in 96-well plates in serum-free medium and compared to control, serum-free medium alone. *p < 0.05 comparing agonist to 
untreated in each group. (C) MeWo or OVCAR-3 cells were plated in 96-wells prior to transfection with the indicated siRNA conditions. The LPA1/3 
antagonist, VPC32183 (20 μM) was added to the cells and viability was assessed. *p < 0.05, ***p < 0.001 comparing treated vs. untreated in each trans-
fection condition. (D) MeWo cells were plated in 96-wells prior to transfection with the indicated siRNAs for 24 h and treatment with Thio-ccPA 18:1 
(50 μM) in serum-containing medium. Cell viability was assessed and the siNegative control was normalized to 100%. ***p < 0.001 comparing treated 
vs. untreated in each transfection condition.Altman et al. Molecular Cancer 2010, 9:140
http://www.molecular-cancer.com/content/9/1/140
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If expression patterns reflect biomarker signatures that
confer susceptibility to thio-ccPA 18:1, we were curious
how prevalent high levels of ATX and the LPA3 receptor
expression are in melanoma. For this we profiled gene
expression microarray data downloaded from the NCBI
Gene Expression Omnibus. Among patient specimen
datasets (GSE7553, N = 87) [33], gene expression analyses
reveals significant variation of LPA3 receptor expression
in metastatic melanoma (Fig. 7A), suggesting that not all
types of advanced melanoma might be strongly suscepti-
ble to thio-ccPA 18:1. This is consistent with the variation
in LP A3 receptor expression we observed among mela-
noma cell lines. We also detected a significantly increased
level of ATX among metastatic melanoma specimens (N
= 40) compared with basal cell carcinoma (N = 15), nor-
mal skin (N = 5) and squamous cell carcinoma of the skin
(N = 11) (Fig. 7B and 7C). ATX expression in primary
melanoma (N = 14) is also increased in comparison to
melanoma in situ, basal and squamous cell carcinoma.
Taken together, the data suggests that a portion of meta-
static melanomas, estimated at approximately 20%,
express high levels of ATX and/or the LPA3 receptor and
this population represents the most appealing pool for
therapeutic intervention.
Discussion
Thio-ccPA 18:1 is a unique compound with multiple tar-
gets. Biological testing of thio-ccPA 18:1 demonstrated it
is an antagonist of the LPA1 and LPA3 receptors along
with its activity as an effective inhibitor of ATX [27].
Thus, the compound is described as having a "one-two-
punch" [39] because it inhibits the generation of LPA and
the initiation of LPA-mediated signaling through LPA1
and LPA3 receptors.
In this study, we demonstrate the in vitro and in vivo
efficacy of thio-ccPA 18:1 and describe its dualistic mech-
anism of action, responsible for decreasing in vitro viabil-
ity in melanoma cells. Either addition of thio-ccPA 18:1
Figure 6 Thio-ccPA 18:1 reduces metastatic melanoma lesions in murine lungs. C57/BL6 mice (N = 27) were injected with 5 × 104 B16F10 cells 
into the tail vein. Thio-ccPA 18:1 was administered on days 3 and 7 during the 21-day study. (A) Necropsy images of left lung lobes demonstrate the 
presence of tumor. Quantification of tumor revealed a reduction in nodules on the lungs shown as both scatter (B) and bar (C) graphs. **p < 0.01 
comparing control (PBS) with thio-ccPA 18:1 treated groups. (D) Quantification of additional lesions detected on organs outside the lungs (kidney, 
liver, pancreas and intestines) and presented as a percentage of mice in each group (Control N = 17, 100%; thio-ccPA 18:1 N = 2 of 10, 20%; thio-ccPA 
18:1).Altman et al. Molecular Cancer 2010, 9:140
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or siRNA for the LPA3 receptor significantly reduces
A375, MeWo and B16F10 melanoma cell viability in vitro
suggesting that the effects may be generalizable to mela-
noma cells. In addition, siLPA3 reduces the membrane
integrity and proliferation of A375 cells and alters cell
morphology. Neither thio-ccPA 18:1 nor siLPA3 induced
nuclear fragmentation (unpublished observations), sug-
gestive of a non-apoptotic mechanism of reduced cell via-
bility. We also show that in vivo treatment with thio-ccPA
18:1 inhibits B16F10 cell metastatic lesions that develop
in the lungs and prevents the spread of metastases to dis-
tant organ.
Previous studies have examined carba analogues of
cyclic phosphatidic acid that inhibit ATX activity [24,25].
Our collaborative study suggested that ATX is a major
mediator of melanoma metastasis in vivo and cancer cell
invasion in vitro and that these analogues work effectively
by inhibiting ATX activity, without receptor antagonism
[24]. Indeed, studies demonstrating the anti-metastatic
capability of ccPA compounds suggested this effect did
not require inhibition of LPA receptor activation [25].
However, these observations did not address whether
coupling A TX inhibition with receptor blockade would
be more effective than targeting ATX alone or whether
different populations of melanoma cells have specific LPA
receptor targeting susceptibilities.
Other studies have confirmed that ATX inhibitors
reduce melanoma cell migration and invasion [40]. ATX
continues to be an important therapeutic target for can-
cer because it may be involved in protecting cells from
apoptosis-induced chemotherapy [41]. Besides mela-
noma, ATX may also play a role in the motility of glio-
blastoma cells, which may be critical due to the high
expression of ATX among the CNS and glioblastoma
multiforme [36]. We have also shown that carba ana-
logues of cyclic phosphatidic acid inhibit the LPA-stimu-
lated motility of prostate cancer cells [29]. In other
diseases, ATX may provide a useful serum biomarker for
follicular lymphoma [42] and chronic hepatitis C [43].
Unlike ATX, there are few studies devoted to the inves-
tigation of the efficacy of targeting the LPA3 receptor.
Our current study enhances the biological understanding
of LPA3 receptor function and these findings are a major
novelty of this study. Our previous study suggested the
increased presence of any of the LPA1, LPA2 or LPA3
receptors enhances tumorgenicity and aggressiveness of
ovarian cancer [30]. Thus far, the only known indepen-
dent function of the LPA3 receptor occurs in reproduc-
tive biology where it regulates embryo implantation and
spacing [44]. Another study suggests women with endo-
metriosis have decreased expression of the LPA3 receptor
in the endometrium, suggesting a hypothesis for their
observed subfertility [45].
The study presented herein is the first to suggest that
the LPA3 receptor plays a crucial role in melanoma cell
viability in vitro. This is the first study to characterize this
unappreciated mechanism of action of the novel com-
pound, thio-ccPA 18:1. It fills a gap in our knowledge
about novel ccPA compounds designed to inhibit LPA
signaling because it highlights a role for receptor antago-
nism, in addition to blocking ATX activity. The fact that
compounds which inhibit ATX are potent agents against
tumor progression is intriguing but leads to an obvious
mechanistic question - why does inhibiting the produc-
tion of LPA have potent biological effects? Based on our
data, we hypothesize that the lack of LPA production
resultant from ATX inhibition leads to a critical reduc-
tion of LPA receptor-mediated survival signaling
required for viability among specific populations of mela-
noma cells.
One limitation of our study surrounds the intrinsic
properties of siRNA and their utility. We used gene
Figure 7 A subset of melanomas express high levels of the LPA3 receptor and ATX. Gene expression microarray data was downloaded from the 
NCBI Gene Expression Omnibus containing patient specimen datasets (GSE7553, N = 87) [33]. The genes (A) LPA3 and (B and C) ATX (ENPP2 A and B) 
were selected and the data was converted into box plot graphs to demonstrate the range of expression levels among these genes.Altman et al. Molecular Cancer 2010, 9:140
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silencing to target individual LPA receptors to verify the
receptor antagonist properties of thio-ccPA 18:1; how-
ever , off-target activity of siRNAs can lead to com plex
interpretations of observed phenotypes. Studies using
microarray gene expression profiling previously sup-
ported the notion that induction of siRNA would specifi-
cally silence the intended target but it is now
acknowledged that off-target activity can occur and is not
ameliorated by decreasing the siRNA concentration [46].
In our study we cannot rule out the possibility that siRNA
of the LPA3 receptor (or siRNA for ATX or any other
LPA receptor) may have off-target effects through
microRNA-like down regulation; however, we are using
pooled siRNA reagents which reduces the overall number
of off-targets through competition among siRNAs. In
addition, we observe a similar reduction in cell viability
using either thio-ccPA 18:1 or VPC32183. This suggests
both the receptor antagonism of the compounds and
siRNA are all targeting the same receptor and the pheno-
type is identical. Therefore, this limitation is not a major
concern since specific antagonists targeting the LPA3
receptor significantly reduced cell viability in MeWo cells.
Finally, we used a novel approach of ion chromatography
and UV detection to demonstrate that the siRNA was
incorporated into the cells. This technique showed that
each of the four siRNAs contained in the SMAR T pool
entered the cells.
The findings of our study have several future therapeu-
tic and translational potentials. The data suggests target-
ing the LPA signaling pathway has efficacy against tumor
progression, in particular against metastatic melanoma.
It compliments previous studies [24,25] and strengthens a
need for further research using melanoma models that
we are currently undertaking. The pattern of LPA recep-
tor expression in melanoma cells may be important to
understanding how the elimination of one receptor,
which is presumably part of a redundant signaling family,
results in a marked decrease in viability. For example, Lee
et al. suggested that it is not merely the expression of the
LPA1 receptor which controls LPA-mediated cell motility
as previously suggested [47], but the lack of LPA4 recep-
tor expression that affects motility as it would otherwise
r e gu la t e  fu n ct i o n  o f  t h e  LP A 1  r ec ep t o r  [ 4 8 ] .  A  s i m i la r
dualistic mechanism could account for LPA-mediated cell
viability and that expression of this yet unknown counter-
r egula ting pr ot ein or r ec eptor is absent in t hese me la-
noma cells. Finally, it is important to clarify the molecular
mechanism of action of pharmaceutical compounds to
improve lead compound design and predict potential side
effects that may appear during clinical and preclinical tri-
als so they can be monitored and managed appropriately.
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